Amidst mounting industry challenges, uncertainty in deal prospects, and new external pressures, Destination XL Group has revealed an unexpected change at the top of its leadership team.
Lionel Conacher Steps In as Interim CEO and Maintains Board Chair Role
Harvey Kanter resigned as CEO and board member of DXL Group on Tuesday, according to a company announcement. DXL, known for its big-and-tall men’s apparel stores, named board chair Lionel Conacher as the interim CEO the following day, with Conacher set to retain his chairmanship during this interim period.
This leadership handoff is happening at a crucial juncture for DXL. Although Kanter’s contract had been extended approximately a year prior, with his departure anticipated at about this time, the company had not publicly named a successor in advance, prompting questions around the readiness for this transition.
Unresolved Merger, Buyout Bids, and Shifting Market Dynamics
The company’s recent change in leadership coincides with mounting strategic uncertainty. Plans for a potential combination with FullBeauty Brands, a women’s plus-size retailer, were first disclosed late last year but have since stalled. Recently, DXL’s board affirmed that it no longer believes the deal aligns with the best interests of the company or its shareholders, pointing to serious issues with FullBeauty’s debt burden and equity valuation.
At the same time, DXL faces outside takeover interest—most notably from Zodiac Partners, a financial firm that put forward a roughly $46 million acquisition offer. The company’s board declined Zodiac’s bid in May and later turned down a revised proposal, maintaining its position despite evolving negotiations.
Mounting Industry Headwinds
Beyond buyouts and mergers, the retailer must also contend with broader industry pressures. DXL’s leadership has identified the rising use of weight-loss drugs as a disruptive force in the plus-size apparel sector, creating unstable sales patterns. Nonetheless, both DXL and FullBeauty have continued to assert that there are ongoing opportunities in this market, even as consumer habits shift alongside the increased adoption of these medications.
In a statement about the leadership transition, Lionel Conacher underscored the board’s commitment to finding a new CEO ready to meet current challenges. He shared plans for a “thorough search” to pinpoint a leader capable of advancing the company’s “strategic priorities and capture the opportunities ahead in a dynamic consumer environment.” Harvey Kanter, referencing Conacher’s depth of experience in mergers and acquisitions, expressed confidence in the board chair’s ability to oversee this pivotal period—particularly given the still unresolved FullBeauty merger and the unsolicited offers from Zodiac.
Future Outlook for DXL
With new interim leadership, DXL now faces a period defined by fluctuating consumer demand, acquisition interest, and a reconsidered partnership with FullBeauty Brands. Identifying the right executive will be essential as DXL looks to guide the company—and its shareholders—toward lasting growth amid these shifting circumstances.